Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Lancet Glob Health. 2018 Apr;6(4):e411–e425. doi: 10.1016/S2214-109X(18)30027-5

Figure 3. Prior and posterior distributions of the adjusted effect of the intervention in Boulkiemdé and in Nayala and Sanguié.

Figure 3

Variables adjusted for in the different models are reported in table 1. (A) Effectiveness measure 1 (prevalence proportion ratio adjusted for the change from baseline to the pre-randomisation period to the post-randomisation period and for clustering by village) and analytical sample 1 (participants provided a blood sample at all three visits). (B) Effectiveness measure 2 (cumulative incidence ratio adjusted for the change from seroconversion from the baseline to the pre-randomisation period and clustering by village) and analytical sample 1. (C) Effectiveness measure 1 and analytical sample 3 (participants provided blood samples at baseline and at the post-randomisation visit). (D) Effectiveness measure 1 and analytical sample 2 (participants provided a blood sample at least once). (E) Effectiveness measure 3 (cumulative incidence ratio from baseline to the post-randomisation visit) and analytical sample 3.